Japanese

News Release

Presentation at the 77th Annual Meeting of the Japanese Cancer Association (JCA2018)

YNP001 study is a First-in-Human study of the cancer peptide vaccine CYT001, a combination immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol, for patients (total 17) with advanced or metastatic solid cancer.
Yamaguchi University Professor Dr. Shoichi Hazama commented, “The results of the study suggest several notable effects; especially strong CTL induction in most of patients, control of tumor makers in more than half of patients, and suppression of several important exhaustion markers on peripheral broods after treatment. I am sure that further analysis will give us evidences for the combination with anti-PD-1 antibody checkpoint inhibitor to improve the therapeutic effects, and that is the way for us to explore.”
CYTLIMIC’s President and CEO, Dr. Shun Doi, said, “I am pleased with the results of YNP01 study, and on the basis of the discoveries of this study we will further explore new application of the vaccine including the combination with other immunotherapies to increase therapeutic effects.”
YNP01 study: A phase I study of combination immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol for patients with advanced or metastatic solid cancer (PI: Hiroaki Nagano, MD, PhD, Professor and Chairman, Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Co-Investigator: Shoichi Hazama, MD, PhD, Professor, Department of Translational Research and Developmental Therapeutics against Cancer, Yamaguchi University School of Medicine, Collaboration: NEC Corporation, Cytlimic Inc.) (UMIN000020440)

PAGETOP